Seppo Ylä-Herttuala secures a 1.3 million Horizon Europe grant for the development of gene therapy for a rare cardiac disease
Europe’s research and innovation funding programme Horizon Europe has granted the GEREMY consortium 8 million euros of funding for the development of new effective therapies for rare diseases. The research group of the GeneCellNano Flagship Director, Professor Seppo Ylä-Herttuala at the University of Eastern Finland is a member of this consortium and secured a grant of 1.3 million euros.
The aim of the project is to find a cure for inherited arrhythmogenic cardiomyopathy (ACM). The research will include engineering disease models for proper assessment of therapeutic interventions and aims to provide in vitro and in vivo preclinical proof-of-concept for various promising gene therapy approaches. The consortium comprises of experts in preclinical and clinical research and cardiac genetics, with all the expertise required to take the gene therapy approach to clinical trials at the end of the project.
Full press release: https://www.uef.fi/en/article/seppo-yla-herttuala-secures-a-13-million-horizon-europe-grant-for-the-development-of-gene-therapy